natgillin/translations-raw huggingface dataset:
Quality of life in psoriatic arthritis patients was assessed at every timepoint using the disability index of the HAQ.
Kakovost življenja bolnikov s psoriatičnim artritisom je bila ocenjena v vsaki časovni točki z uporabo indeksa invalidnosti po HAQ.
Tell your doctor or pharmacist if you or the child are taking, have recently taken or might take any other medicines (including anakinra, abatacept or sulfasalazine), even those not prescribed by the doctor.
Obvestite zdravnika ali farmacevta, če vi ali otrok jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katerokoli drugo zdravilo (vključno z anakinro, abataceptom ali sulfasalazinom), tudi če ste ga dobili brez recepta.
PASI 50 14 58* 70 74* 77 9
PASI 50 14 58* 70 74* 77 9 PASI 75 4 34* 44 49* 59 3 DSGAb,
Women of childbearing potential should consider the use of appropriate contraception to avoid becoming pregnant during Erelzi therapy and for three weeks after discontinuation of therapy.
Ženske v rodni dobi morajo razmisliti o uporabi ustrezne kontracepcije za preprečitev nosečnosti med zdravljenjem z zdravilom Erelzi in še tri tedne po prenehanju zdravljenja.
Some children and teenage patients who have received Erelzi or other medicines that work the same way as Erelzi have developed cancers, including unusual types, which sometimes resulted in death.
Pri nekaterih otrocih in mladostnikih, ki so prejemali zdravilo Erelzi ali druga podobna zdravila z enakim načinom delovanja kot zdravilo Erelzi, se je razvil rak, vključno z neobičajnimi oblikami, ki se je včasih končal s smrtjo.
What Erelzi is and what it is used for What you need to know before you use Erelzi How to use Erelzi
Kaj je zdravilo Erelzi in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Erelzi Kako uporabljati zdravilo Erelzi
• if you, or the child you are caring for, are allergic to etanercept or any of the other ingredients of Erelzi (listed in section 6).
• če ste vi ali otrok, za katerega skrbite, alergični na etanercept ali katerokoli sestavino tega zdravila Erelzi (navedeno v poglavju 6).
Treatment with etanercept 25 mg resulted in substantial improvement at 12 months, with about 44% of patients achieving a normal HAQ score (less than 0.5).
Z zdravljenjem s 25 mg etanercepta so dosegli bistveno izboljšanje pri 12 mesecih - približno 44 % bolnikov je doseglo normalen rezultat HAQ (manj kot 0,5).
If you forget to inject Erelzi
Če ste si pozabili injicirati zdravilo Erelzi
The primary measure of efficacy (ASAS 20) was a ≥ 20% improvement in at least 3 of the 4
Primarno merilo učinkovitosti (ASAS 20) je bilo ≥ 20 % izboljšanje pri vsaj 3 od 4 domen lestvice
This appearance is normal for Erelzi.
Tak izgled je normalen za zdravilo Erelzi.
Erelzi is administered by subcutaneous injection (see section 6.6).
Zdravilo Erelzi se daje s subkutano injekcijo (glejte poglavje 6.6).
Treatment with Erelzi should not be initiated in patients with active infections, including chronic or localised infections.
Zdravljenja z zdravilom Erelzi ne smete uvesti pri bolnikih z aktivnimi okužbami, vključno s kroničnimi ali lokaliziranimi okužbami.
• Alcohol abuse: Erelzi should not be used for the treatment of hepatitis related to alcohol abuse.
• Zloraba alkohola: Zdravila Erelzi ne smete uporabljati za zdravljenje hepatitisa, povezanega z zlorabo alkohola.
For patients with multiple symmetrical painful or swollen joints (e.g., hands, wrists and feet), Erelzi can slow down the structural damage to those joints caused by the disease.
Pri bolnikih z več simetrično prizadetimi bolečimi ali oteklimi sklepi (npr. dlanmi, zapestji ali stopali) lahko zdravilo Erelzi upočasni razvoj strukturnih okvar teh sklepov, ki jih povzroča bolezen.
The exposure-adjusted rate was 0.06 events per 100 patient-years.
Za stopnjo izpostavljenosti prilagojena pogostnost je bila 0,06 dogodka na 100 bolnikov-let.
Because immunoglobulins, in common with many medicinal products, can be excreted in human milk, a decision must be made whether to discontinue breast-feeding or to discontinue Erelzi therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Ker se imunoglobulini, tako kot mnoga druga zdravila, lahko izločajo v mleko pri človeku, se je treba odločiti, ali bo med zdravljenjem z zdravilom Erelzi bolnica prenehala dojiti ali pa bo med dojenjem prekinila zdravljenje s tem zdravilom, pri čemer je treba upoštevati tako korist dojenja za otroka kot korist zdravljenja za mater.
In placebo-controlled trials, no increase in the incidence of serious infections (fatal, life-threatening, or requiring hospitalisation or intravenous antibiotics) was observed.
V preskušanjih, nadzorovanih s placebom, niso opazili zvečanja pojavnosti resnih okužb (s smrtnim izidom, življenjsko ogrožajočih okužb ali takih, ki so zahtevale hospitalizacijo ali intravenske antibiotike).
If you feel that the effect of Erelzi is too strong or too weak, talk to your doctor or pharmacist.
Če menite, da je učinek zdravila Erelzi premočan ali prešibak, se posvetujte z zdravnikom ali farmacevtom.
No rebound flare of disease and no psoriasis-related serious adverse events were observed.
Opazili niso nobenega povratnega izbruha bolezni in nobenih s psoriazo povezanih resnih neželenih učinkov.
The educational material is intended to prevent or reduce potential medication errors related to improper use of Erelzi prefilled-pen (autoinjector (AI):
Izobraževalno gradivo je namenjeno preprečevanju ali zmanjševanju števila morebitnih napak pri zdravljenju, povezanih z nepravilno uporabo napolnjenih injekcijskih peresnikov (avtoinjektorjev) z zdravilom Erelzi:
common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data).
< 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000);
• Very rare (may affect up to 1 in 10,000 people): Failure of the bone marrow to produce crucial blood cells.
• Zelo redki (pojavijo se lahko pri največ 1 od 10.000 bolnikov): prenehanje tvorbe nujnih krvnih celic v kostnem mozgu.
Inspect the solution in the pen by looking through the clear viewing window.
Preglejte raztopino v brizgi s pogledom skozi prozorno pregledno okence.
If inactive (‘latent') tuberculosis is diagnosed, treatment for latent tuberculosis must be started with anti-tuberculosis therapy before the initiation of Erelzi, and in accordance with local recommendations.
Če se ugotovi neaktivna ('latentna') tuberkuloza, je treba pred uvedbo zdravila Erelzi in v skladu z nacionalnimi priporočili začeti zdravljenje latentne tuberkuloze z antituberkulozno terapijo.
Erelzi works by reducing the inflammation associated with certain diseases.
Deluje tako, da zmanjšuje vnetje, ki spremlja določene bolezni.
When you are ready to use the syringe, open the blister and wash your hands thoroughly with soap and water.
Ko boste pripravljeni na injiciranje z injekcijsko brizgo, odprite pretisni omot in si temeljito umijte roke z milom in vodo.
It is recommended that you record the date that Erelzi is removed from the refrigerator and the date after which Erelzi should be discarded (no more than 4 weeks following the removal from the refrigerator).
Priporočljivo si je zabeležiti datum odvzema zdravila Erelzi iz hladilnika in datum, po katerem je treba zdravilo Erelzi zavreči (do 4 tedne po odvzemu iz hladilnika).
Etanercept did not induce lethality or notable signs of toxicity in mice or rats following a single subcutaneous dose of 2,000 mg/kg or a single intravenous dose of 1,000 mg/kg.
Etanercept ni povzročil smrtnosti ali pomembne toksičnosti pri miših ali podganah po enkratnem subkutanem odmerku 2.000 mg/kg ali enkratnem intravenskem odmerku 1.000 mg/kg.
Etanercept was significantly better than placebo in all measures of disease activity (p < 0.001), and responses were similar with and without concomitant methotrexate therapy.
Etanercept je bil pomembno boljši kot placebo po vseh kriterijih aktivnosti bolezni (p < 0,001) in odzivi so bili podobni, ne glede na sočasno zdravljenje z metotreksatom ali brez.
In this situation, the benefit/risk balance of Erelzi therapy should be very carefully considered.
V takem primeru je treba zelo skrbno pretehtati razmerje med koristmi in tveganji zdravljenja z zdravilom Erelzi.
• Do not touch the cleaned area again before injecting.
• Pred injiciranjem se očiščenega mesta ne dotikajte več.
This card provides important safety information for patients, including information relating to infections and to worsening of congestive heart failure related to Erelzi.
Na tej kartici so zbrani pomembni varnostni podatki za bolnike, vključno s podatki o okužbah in poslabšanju kongestivnega srčnega popuščanja, ki se povezujejo z zdravilom Erelzi.
Simulation of dosing suggests that while older children (1017 years of age) will have serum levels close to those seen in adults, younger children will have appreciably lower levels.
Simulacija odmerjanja kaže, da bodo imeli starejši otroci (10 do 17 let) podobne serumske koncentracije kot odrasli, mlajši otroci pa znatno nižje.
The safety and efficacy profiles of the two etanercept treatment regimens were comparable at week 8 in their effect on signs and symptoms of RA; data at week 16 did not show comparability (non-inferiority) between the two regimens.
Profil varnosti in učinkovitosti obeh shem zdravljenja z etanerceptom je bil po 8 tednih primerljiv glede učinka na znake in simptome revmatoidnega artritisa; podatki po 16 tednih niso pokazali primerljivosti (neinferiornosti) med obema shemama.
Etanercept N = 103 to 105*
Etanercept n = 103 do 105*
Patients who develop a new infection while undergoing treatment with Erelzi should be monitored closely.
Bolnike, pri katerih se med zdravljenjem z zdravilom Erelzi pojavi nova okužba, je treba skrbno spremljati.
The central volume of distribution of etanercept is 7.6 l, while the volume of distribution at steady-state is 10.4 l. Elimination
Osrednji volumen porazdelitve etanercepta je 7,6 l, volumen porazdelitve v stanju dinamičnega ravnovesja pa je 10,4 l.
You or the child should not use Erelzi with medicines that contain the active substance anakinra or abatacept.
Zdravila Erelzi vi ali otrok ne smete jemati skupaj z zdravili, ki vsebujejo učinkovino anakinro ali abatacept.
Do not mix the Erelzi solution with any other medicine.
Raztopine zdravila Erelzi ne smete mešati z nobenim drugim zdravilom.
• Press the pen firmly against the skin to start the injection.
• Injekcijski peresnik močno pritisnite proti koži, da se injiciranje lahko začne.
The combination etanercept and anakinra has not demonstrated increased clinical benefit, and is therefore not recommended.
Kombinacija etanercepta in anakinre ni pokazala povečane klinične koristi, zato ni priporočljiva.
Never leave the syringe lying around where others might tamper with it.
Injekcijske brizge nikoli ne puščajte ležati naokoli, da ne bi nanjo naleteli drugi ljudje.
• Tuberculosis: As cases of tuberculosis have been reported in patients treated with Erelzi, your doctor will check for signs and symptoms of tuberculosis before starting Erelzi.
• Tuberkuloza: Ker so pri bolnikih, ki so se zdravili z zdravilom Erelzi, poročali o primerih tuberkuloze, se bo vaš zdravnik prepričal, da nimate znakov ali simptomov tuberkuloze, preden se boste začeli zdraviti z zdravilom Erelzi.
Pharmacotherapeutic group: Immunosuppressants, tumour necrosis factor alpha (TNF-α) inhibitors, ATC code: L04AB01
Farmakoterapevtska skupina: Zdravila za zaviranje imunske odzivnosti, Zaviralci tumorje nekrotizirajočega faktorja alfa (TNF-α), oznaka ATC: L04AB01
If you have used more Erelzi than you should (either by injecting too much on a single occasion or by using it too frequently), talk to a doctor or pharmacist immediately.
Če ste uporabili večji odmerek zdravila Erelzi, kot bi smeli Če ste uporabili večji odmerek zdravila Erelzi, kot bi smeli (bodisi ste ga naenkrat injicirali preveč bodisi prepogosto), se nemudoma posvetujte z zdravnikom ali farmacevtom.
Efficacy response in placebo-controlled nr-AxSpa study: percent of patients achieving endpoints
Odziv glede učinkovitosti v s placebom nadzorovani študiji nr-AxSpa: Odstotek bolnikov, ki so dosegli opazovane dogodke
Slowly press the plunger as far as it will go, so that the plunger head is completely between the needle guard wings.
Počasi potiskajte bat, dokler gre, tako da se na koncu glava bata povsem usede med krila zapirala igle.
Etanercept treatment may increase mortality in patients with established sepsis.
Zdravljenje z etanerceptom lahko zveča smrtnost pri bolnikih z dokazano sepso.
On the basis of the scientific conclusions for etanercept (biosimilars) the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing etanercept (biosimilars) is unchanged subject to the proposed changes to the product information
Na podlagi znanstvenih zaključkov za etanercept (podobna biološka zdravila) odbor CHMP meni, da je razmerje med koristjo in tveganjem zdravil(-a), ki vsebuje(-jo) etanercept (podobna biološka zdravila), nespremenjeno ob upoštevanju predlaganih sprememb v informacijah o zdravilu.
Such symptoms may point to the existence of potentially life-threatening blood disorders, which may require discontinuation of Erelzi.
Ti simptomi namreč lahko kažejo na pojav življenjsko ogrožajoče bolezni krvi, pri kateri bo zdravljenje z zdravilom Erelzi morda treba prekiniti.
• A visually engaging instruction guide demonstrating step-by-step procedure for the use of the AI will be developed and distributed to nurses and HCPs to facilitate training of patients and staff in the prescriber´s office or during a homecare program
• oblikovana bodo grafično učinkovita navodila s podrobno prikazanim postopkom uporabe avtoinjektorja, ki bodo razdeljena medicinskim sestram in zdravstvenim delavcem za lažje poučevanje bolnikov in osebja v ambulanti predpisovalca ali v programu zdravstvene oskrbe na domu;
Slowly release the plunger and allow the needle guard to automatically cover the exposed needle.
Počasi spustite bat in pustite, da zapiralo igle samodejno pokrije izpostavljeno iglo.
Children and adults taking Erelzi may have an increased risk of developing lymphoma or another cancer.
Pri otrocih in odraslih, ki prejemajo zdravilo Erelzi, je morda tveganje za nastanek limfoma ali druge oblike raka večje.
The syringe cannot be re-used.
Injekcijske brizge ne smete ponovno uporabiti.
If any serious allergic or anaphylactic reaction occurs, Erelzi therapy should be discontinued immediately and appropriate therapy initiated.
Če se pojavi kakršna koli resna alergijska ali anafilaktična reakcija, je treba zdravljenje z zdravilom Erelzi takoj prekiniti in uvesti ustrezno zdravljenje.
Erelzi is not indicated for use in children and adolescents who weigh less than 62.5 kg.
Zdravilo Erelzi ni indicirano za uporabo pri otrocih in mladostnikih, ki tehtajo manj kot 62,5 kg.
There have been post-marketing reports of interstitial lung disease (including pneumonitis and pulmonary fibrosis), some of which had fatal outcomes.
V obdobju trženja so poročali o intersticijski bolezni pljuč (vključno s pnevmonitisom in pljučno fibrozo), nekateri od teh primerov so bili tudi smrtni.
For psoriatic arthritis patients with multiple joint involvement, Erelzi can improve your ability to do normal daily activities.
Pri bolnikih s psoriatičnim artritisom in prizadetostjo več sklepov lahko zdravilo Erelzi izboljša sposobnost opravljanja običajnih vsakdanjih dejavnosti.
The following list of adverse reactions is based on experience from clinical trials in adults and on post-marketing experience.
Preglednica neželenih učinkov Spodnji seznam neželenih učinkov temelji na izkušnjah iz kliničnih preskušanj pri odraslih ter na izkušnjah iz obdobja trženja.
If an alternate dose is required, other etanercept products offering such an option should be used.
Če je potreben drugačen odmerek, je treba uporabiti druga zdravila z etanerceptom, ki to omogočajo.
Be careful not to touch the needle guard wings before use.
Pazite, da se pred odmerjanjem ne boste dotikali kril zapirala igle.
Erelzi is not recommended for the treatment of Wegener's granulomatosis.
Zdravila Erelzi ni priporočljivo uporabljati za zdravljenje Wegenerjeve granulomatoze.
If Erelzi has no effect on the child's condition after 12 weeks, your doctor may tell you to stop using this medicine.
Če zdravilo Erelzi po 12 tednih nima nobenega učinka na otrokovo stanje, vam bo zdravnik morda naročil, da prenehajte uporabljati to zdravilo.
Keep the plunger pressed fully down while you hold the syringe in place for 5 seconds.
Bat držite pritisnjen do konca in brizgo zadržite v istem položaju 5 sekund.
In patients who develop HBV infection, Erelzi should be stopped and effective anti-viral therapy with appropriate supportive treatment should be initiated.
Pri bolnikih, pri katerih se razvije okužba s HBV, je treba zdravljenje z zdravilom Erelzi prekiniti in uvesti učinkovito protivirusno ter ustrezno podporno zdravljenje.
If Erelzi has no effect on your condition after 12 weeks, your doctor may tell you to stop using this medicine.
Če zdravilo Erelzi po 12 tednih nima nobenega učinka na vašo bolezen, vam zdravnik lahko naroči, da to zdravilo nehate uporabljati.
• Reminder that Erelzi should not be used in children and adolescents weighing less than 62.5 kg.
• opozorilo, da se zdravila Erelzi ne sme uporabljati pri otrocih in mladostnikih, ki tehtajo manj kot 62,5 kg;
In a 48-week study in 211 children aged 4 to 17 years with paediatric plaque psoriasis, the adverse events reported were similar to those seen in previous studies in adults with plaque psoriasis.
V 48-tedenski študiji pri 211 otrocih, starih 4 do 17 let, z otroško psoriazo v plakih so bili poročani neželeni učinki podobni tistim, ki so jih opažali v predhodnih študijah pri odraslih s psoriazo v plakih.
You can press a cotton ball or gauze over the injection site and hold it for 10 seconds.
Na to mesto lahko pritisnete kosem vate ali zloženec iz gaze in ga držite 10 sekund.
Consequently, Erelzi should not be used in patients for the treatment of alcoholic hepatitis.
Zato zdravila Erelzi ne smemo uporabljati pri bolnikih za zdravljenje alkoholnega hepatitisa.
• Request to ask the doctor to record test, date and results of last TB screening on the alert card
• napotek bolniku, naj zdravnika prosi, da na opozorilno kartico za bolnika vpiše datum in rezultate zadnjega presejalnega testa za TB;
If active tuberculosis is diagnosed, Erelzi therapy must not be initiated.
Če je postavljena diagnoza aktivne tuberkuloze, se zdravljenja z zdravilom Erelzi ne sme uvesti.
If it has expired, return the entire pack to the pharmacy.
Če zdravilu poteče rok uporabnosti, celotno pakiranje vrnite v lekarno.
Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs).
Zdravljenje odraslih s hudim radiografsko nezaznavnim aksialnim spondilartritisom in objektivnimi znaki vnetja (na katerega kažejo povišana vrednost C-reaktivnega proteina (CRP) in/ali dokazi magnetnoresonančnega slikanja (MRI)), ki imajo nezadostni odziv na nesteroidna protivnetna zdravila
Placebo N = 106 to 109*
Placebo n = 106 do 109*
A placebo-controlled trial, in which 89 adult patients were treated with etanercept in addition to standard therapy (including cyclophosphamide or methotrexate, and glucocorticoids) for a median duration of 25 months, has not shown etanercept to be an effective treatment for Wegener's granulomatosis.
Wegenerjeva granulomatoza S placebom nadzorovano preskušanje, v katerem je 89 odraslih bolnikov poleg standardnega zdravljenja (vključno s ciklofosfamidom ali metotreksatom in glukokortikoidi) jemalo etanercept z medianim časom zdravljenja 25 mesecev, ni pokazalo učinkovitosti etanercepta za zdravljenje Wegenerjeve granulomatoze.
• Not known (frequency cannot be estimated from the available data): Merkel cell carcinoma (a type of skin cancer); excessive activation of white blood cells associated with inflammation (macrophage activation syndrome); recurrence of hepatitis B (a liver infection); worsening of a condition called dermatomyositis (muscle inflammation and weakness with an accompanying skin rash).
• Neznana (pogostnosti iz razpoložljivih podatkov ni mogoče oceniti): karcinom Merklovih celic (vrsta kožnega raka); čezmerna aktivacija belih krvničk, povezanih z vnetjem (sindrom aktivacije makrofagov); ponovitev hepatitisa B (vnetje jeter); poslabšanje stanja, imenovanega dermatomiozitis (vnetje mišic in mišična oslabelost, ki ju spremlja kožni izpuščaj).
• Free lines to record brand name and batch number
• prazne črte za zapis trgovskega imena in številke serije.
The incidence of non-cutaneous malignancies of various types was significantly higher in patients treated with etanercept than in the control group.
Pojavnost nekožnih malignih obolenj različnih tipov je bila pomembno večja pri bolnikih, zdravljenih z etanerceptom, kot pri tistih v kontrolni skupini.
ASAS 70 2 weeks
ASAS 70 2 tedna
ASAS 50 2 weeks
ASAS 50 2 tedna
Within the system organ classes, adverse reactions are listed under headings of frequency (number of patients expected to experience the reaction), using the following categories: very common (≥ 1/10);
Znotraj organskih sistemov so neželeni učinki navedeni po pogostnosti (število bolnikov, pri katerih se pričakuje pojav učinka), z uporabo naslednjih kategorij: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do
In a group of 2,711 plaque psoriasis patients treated with etanercept in double-blind and open-label studies of up to 2.5 years, 30 malignancies and 43 non-melanoma skin cancers were reported.
V skupini 2.711 bolnikov s psoriazo v plakih, zdravljenih z etanerceptom v dvojno slepih in odprtih študijah, ki so trajale do 2,5 leta, so poročali o 30 malignomih in 43 primerih nemelanomskega kožnega raka.
Autoantibody formation Treatment with Erelzi may result in the formation of autoimmune antibodies (see section 4.8).
Tvorba avtoprotiteles Zdravljenje z zdravilom Erelzi lahko sproži nastajanje avtoimunskih protiteles (glejte poglavje 4.8).
Erelzi is a biosimilar medicinal product.
Zdravilo Erelzi je podobno biološko zdravilo.
• Wegener's granulomatosis: Erelzi is not recommended for the treatment of Wegener's granulomatosis, a rare inflammatory disease.
• Wegenerjeva granulomatoza: Zdravilo Erelzi ni priporočljivo za zdravljenje redke vnetne bolezni Wegenerjeve granulomatoze.
If re-treatment with etanercept is indicated, the same guidance on treatment duration should be followed.
Če je indicirano ponovno zdravljenje z etanerceptom, se moramo ravnati po istih smernicah glede trajanja zdravljenja.
Patients treated with Erelzi should be given the Patient Alert Card.
Bolniki, ki se zdravijo z zdravilom Erelzi, naj prejmejo opozorilno kartico za bolnika.
Erelzi may be stored at temperatures up to a maximum of 25 °C for a single period of up to four weeks; after which, it should not be refrigerated again.
Zdravilo Erelzi se lahko shranjuje pri temperaturi do največ 25 °C za enkratno obdobje do štirih tednov, po katerem se ga ne sme več ohladiti.
After a single subcutaneous dose of 25 mg etanercept, the average maximum serum concentration observed in healthy volunteers was 1.65 ± 0.66 µg/ml, and the area under the curve was 235 ± 96.6 µg•hr/ml.
Po enkratnem subkutanem odmerku 25 mg etanercepta je bila povprečna največja koncentracija zdravila v serumu pri zdravih prostovoljcih 1,65 ± 0,66 μg/ml, površina pod krivuljo pa 235 ± 96,6 μg•h/ml.
• Vaccinations: If possible, children should be up to date with all vaccinations before using Erelzi.
• Cepljenja: Najbolje je, da otrok pred začetkom zdravljenja z zdravilom Erelzi opravi vsa predvidena cepljenja.
The use of Erelzi is not expected to affect the ability to drive or use machines.
Ni pričakovati, da bi zdravilo Erelzi vplivalo na sposobnost upravljanja vozil in strojev.